Among the medicines on A.K. Pharma’s product range that generate significant Google search traffic but relatively few clicks, Sybrava stands out. Over 2,000 impressions per month at position 5 — meaning it appears on the first page of Google for thousands of searches — but a click-through rate of under 1%. That gap between visibility and engagement is almost always a content problem, not a ranking problem. People are finding the page but not finding enough information to click through.
This article is the information. Whether you are an oncologist looking for sourcing context, a hospital pharmacist managing HER2-positive breast cancer procurement, or a patient or family member trying to understand what Sybrava is and why it has been prescribed, here is what you need to know.
What Is Sybrava?
Sybrava is the brand name for Neratinib — an oral, irreversible pan-HER tyrosine kinase inhibitor (TKI) developed by Puma Biotechnology and licensed to Pierre Fabre. It is supplied as 40mg film-coated tablets and is taken orally once daily.
The “pan-HER” part of its mechanism is what distinguishes Neratinib from earlier HER2-targeted therapies — where first-generation agents like Trastuzumab (Herceptin) target the HER2 receptor from outside the cell, Neratinib works inside the cell, irreversibly binding to and inhibiting HER2, HER1 (EGFR), and HER4 kinase activity simultaneously. This broader intracellular inhibition is the rationale for Neratinib’s use in patients whose cancer has progressed despite prior HER2-targeted therapy.
The HER2-Positive Breast Cancer Landscape — Context for Sourcing Teams
HER2-positive breast cancer accounts for approximately 15-20% of all breast cancer cases globally, and represents a biologically distinct and historically aggressive subtype that has been transformed by targeted therapy over the past two decades. Understanding where Neratinib sits in the treatment landscape helps procurement teams understand the clinical context for the orders they are placing.
According to published oncology literature and current treatment guidelines, HER2-positive breast cancer treatment has evolved through several generations:
First generation: Trastuzumab (Herceptin) — the original anti-HER2 monoclonal antibody, which transformed HER2+ breast cancer from one of the most aggressive to one of the most treatable subtypes when combined with chemotherapy.
Second generation: Pertuzumab (added to Trastuzumab), Trastuzumab Emtansine (T-DM1/Kadcyla) — extending outcomes in early and metastatic disease.
Third generation and beyond: Neratinib (Sybrava), Trastuzumab Deruxtecan (Enhertu), Tucatinib — newer agents addressing resistance and CNS disease.
Sybrava sits in this third generation, specifically addressing the challenge of disease that has progressed despite prior Trastuzumab-based therapy and the particular issue of brain metastases — a common site of progression in HER2+ breast cancer that many earlier therapies do not adequately penetrate.
For current HER2+ breast cancer treatment guidelines, the American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) publish regularly updated recommendations that provide the clinical context for Neratinib prescribing decisions.
Clinical Evidence — What the Trials Show
ExteNET Trial — Extended Adjuvant Neratinib After Trastuzumab
Published in The Lancet Oncology (2016) and with long-term follow-up data published subsequently, the pivotal ExteNET trial evaluated Neratinib as extended adjuvant therapy for one year following completion of Trastuzumab-based adjuvant chemotherapy in women with early-stage HER2-positive breast cancer. Key findings demonstrated a statistically significant improvement in invasive disease-free survival (iDFS) compared to placebo — with the greatest benefit seen in hormone receptor-positive, HER2-positive patients who initiated Neratinib within one year of completing Trastuzumab. Five-year iDFS rates showed a meaningful absolute benefit in this population, supporting Neratinib’s approval for this extended adjuvant indication.
NALA Trial — Neratinib Plus Capecitabine in Metastatic HER2+ Breast Cancer
Published in the Journal of Clinical Oncology (2020), the NALA trial evaluated Neratinib in combination with Capecite (Capecitabine) versus Lapatinib plus Capecitabine in patients with metastatic HER2-positive breast cancer who had received two or more prior HER2-directed regimens. Key findings demonstrated superior progression-free survival and a significant reduction in the incidence of CNS interventions — interventions required for brain metastases — in the Neratinib arm, which is particularly meaningful given the high rate of CNS progression in HER2+ metastatic breast cancer.
The CNS data from the NALA trial is one of the most cited clinical arguments for Neratinib in the metastatic setting — the ability to reduce the need for brain-directed intervention (radiotherapy, surgery) is a meaningful clinical outcome for patients with HER2+ metastatic disease who are at high risk of CNS progression.
For the full clinical evidence base, the National Cancer Institute’s Neratinib information page and the NCCN HER2-positive breast cancer guidelines provide detailed clinical reference.
Available Strength and Dosing Reference
Sybrava is supplied as 40mg Neratinib film-coated tablets.
| Presentation | Strength | Standard Dose | Duration |
|---|---|---|---|
| Sybrava Tablets | 40mg per tablet | 240mg (six 40mg tablets) once daily | Extended adjuvant: 12 months. Metastatic: until disease progression or unacceptable toxicity |
The standard dose of 240mg once daily is taken with food — taking Neratinib with a meal is important both for absorption and for reducing the severity of gastrointestinal side effects. All dosing decisions, including any required dose reductions for toxicity management, are made by the treating oncologist in accordance with the approved prescribing information.
Indications — What Sybrava Is Used For
Extended Adjuvant Treatment of Early-Stage HER2+ Breast Cancer:
- Adults with HER2-overexpressed or amplified early-stage breast cancer, following adjuvant Trastuzumab-based therapy
- One year of Neratinib treatment following completion of Trastuzumab-based adjuvant chemotherapy
- Hormone receptor-positive patients derive the greatest benefit per the ExteNET trial data
Metastatic HER2+ Breast Cancer:
- Adults with advanced or metastatic HER2-positive breast cancer, in combination with Capecitabine, after two or more prior anti-HER2-based regimens in the metastatic setting
- Supported by the NALA trial showing progression-free survival benefit and reduced CNS intervention rates
For detailed indication information refer to MedlinePlus Neratinib and the FDA Neratinib prescribing information.
Key Benefits of Sybrava
Irreversible Pan-HER Inhibition — A Different Mechanism Than Trastuzumab
Unlike monoclonal antibodies that bind to the extracellular domain of HER2, Neratinib irreversibly inhibits HER2 kinase activity intracellularly — and simultaneously inhibits HER1 and HER4. This broader intracellular blockade can overcome certain resistance mechanisms that develop after prolonged Trastuzumab-based therapy, making Neratinib relevant in the post-Trastuzumab setting.
CNS Activity — Relevant for HER2+ Metastatic Breast Cancer
Brain metastases are a particular challenge in HER2-positive metastatic breast cancer — the blood-brain barrier limits access of many large-molecule HER2-targeted therapies to the CNS. As a small molecule, Neratinib has greater CNS penetration than monoclonal antibodies, and the NALA trial demonstrated a significant reduction in CNS interventions required in the Neratinib arm — a clinically meaningful outcome for patients at high risk of CNS progression.
Oral Administration
Taken as a once-daily oral tablet, Neratinib does not require infusion visits — a practical benefit for patients already managing the demands of ongoing cancer treatment.
Established Evidence Base in Both Early and Metastatic Settings
ExteNET and NALA provide clinical evidence across two distinct settings — early-stage extended adjuvant treatment and metastatic combination therapy — giving oncologists a well-evidenced option in both parts of the HER2+ breast cancer treatment continuum.
Side Effects — What Oncology Teams Need to Know
The dominant side effect with Neratinib is diarrhoea — this is well-documented, clinically significant, and the most important aspect of Sybrava’s side effect profile for both prescribers and procurement teams to understand.
Diarrhoea: Reported in the vast majority of patients in clinical trials, with Grade 3 or higher diarrhoea occurring in a significant proportion without prophylaxis. The critical management advance is loperamide prophylaxis — starting loperamide at the initiation of Neratinib therapy and titrating per protocol significantly reduces the incidence and severity of diarrhoea. This prophylactic approach is now standard of care per the approved prescribing information and is reflected in current clinical guidelines. Hospitals procuring Sybrava should ensure loperamide availability alongside it.
Nausea and vomiting: Commonly reported, particularly early in treatment. Taking Neratinib with food reduces severity.
Fatigue, abdominal pain, decreased appetite: Commonly reported in clinical trials.
Hepatotoxicity: Elevated liver enzymes have been reported — baseline and periodic liver function monitoring is required per the approved prescribing information.
Embryo-fetal toxicity: Neratinib can cause fetal harm — effective contraception is required during and for a defined period following treatment per the approved label.
Full side effect information is available at FDA Neratinib Safety Information and Drugs.com Neratinib.
Precautions
- Diarrhoea prophylaxis — loperamide should be initiated concurrently with Neratinib per the approved prescribing information and current clinical guidance
- Liver function monitoring — baseline and periodic ALT, AST, and bilirubin monitoring required
- Embryo-fetal toxicity — effective contraception required during treatment and for at least one month after the final dose
- Hepatic impairment — dose reduction required in severe hepatic impairment per approved label
- Drug interactions — Neratinib is a substrate of CYP3A4 and P-gp; strong CYP3A4 inhibitors increase Neratinib exposure; strong CYP3A4 inducers decrease it — review concurrent medications carefully
- Proton pump inhibitors — PPIs reduce Neratinib absorption significantly; use of PPIs with Neratinib is not recommended per the prescribing information; antacids should be separated by at least 3 hours
- Refer to manufacturer prescribing information and NCCN HER2+ breast cancer guidelines for complete management context
Storage and Handling
- Store below 25°C
- Store in original packaging protected from moisture
- Keep out of reach of children
As one of Delhi’s most trusted pharmaceutical distribution companies, A.K. Pharma stores all oncology medicines including Sybrava under manufacturer-recommended conditions ensuring product integrity for every supply.
Manufacturer Information
Sybrava (Neratinib) is the Indian brand of Neratinib, manufactured under licence from Puma Biotechnology. The originator product is Nerlynx (approved by FDA in 2017 and EMA in 2018). A.K. Pharma supplies genuine Sybrava sourced from authorised distribution channels. Unlike general wholesale pharmaceutical distributors, A.K. Pharma maintains verified sourcing and complete batch documentation for every oncology medicine it supplies.
Related HER2 and Breast Cancer Medicines Available at A.K. Pharma
- Sybrava (Neratinib) — pan-HER TKI for HER2+ breast cancer
- Enhertu (Trastuzumab Deruxtecan) — ADC for HER2+ and HER2-low breast cancer
- Capecite (Capecitabine) — oral chemotherapy used in combination with Neratinib in the NALA regimen
- Kryxana (Ribociclib) — CDK4/6 inhibitor for HR+/HER2- breast cancer
- Faslodex (Fulvestrant) — endocrine therapy for HR+ breast cancer
- Truqap (Capivasertib) — AKT inhibitor for HR+/HER2- breast cancer
- Elahere (Mirvetuximab Soravtansine) — ADC for FRα-positive ovarian cancer
- Browse all Cancer Medicines at A.K. Pharma
- Browse the full Products range at A.K. Pharma
- Learn about the Named Patient Program for medicines requiring special import access
- Learn about the Patient Assistance Program for eligible patients
Frequently Asked Questions
Q. What is Sybrava used for?
Sybrava (Neratinib) is used for extended adjuvant treatment of early-stage HER2-positive breast cancer following Trastuzumab-based therapy, and in combination with Capecitabine for metastatic HER2-positive breast cancer after two or more prior anti-HER2 regimens, per the approved prescribing information.
Q. What is the generic name and strength of Sybrava?
The generic name is Neratinib, supplied as 40mg film-coated tablets. The standard dose is 240mg (six 40mg tablets) taken once daily with food.
Q. How does Sybrava differ from Trastuzumab (Herceptin)?
Trastuzumab is a monoclonal antibody that binds to the extracellular domain of HER2, blocking signalling from outside the cell. Neratinib is a small-molecule tyrosine kinase inhibitor that irreversibly binds to HER2 (and HER1 and HER4) intracellularly, blocking kinase activity from inside the cell. They work at different points of the HER2 signalling pathway and are used at different stages of treatment.
Q. Why is loperamide prophylaxis important with Sybrava?
Diarrhoea is the most common and clinically significant side effect of Neratinib — reported in the vast majority of patients without prophylaxis. Initiating loperamide concurrently with Neratinib per the approved prophylaxis protocol significantly reduces the incidence and severity of diarrhoea. This is now standard practice per the prescribing information and current clinical guidelines.
Q. Can Sybrava be taken with proton pump inhibitors?
No — proton pump inhibitors (PPIs) significantly reduce Neratinib absorption and should not be used concurrently per the approved prescribing information. Antacids may be used but should be separated from Neratinib by at least 3 hours.
Q. Is Sybrava available in India?
Sybrava can be supplied to hospitals and oncology centres across India through licensed pharmaceutical distributors. Contact A.K. Pharma — one of Delhi’s trusted pharmaceutical distribution companies — for availability and pricing.
Q. What is the price of Sybrava in India?
Sybrava price in India varies by pack size and order quantity. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing.
Q. How to order Sybrava from A.K. Pharma?
Call us at 011 4172 6999 or WhatsApp +91 9810034827 with your requirements and we will respond promptly.
Why Source Sybrava Through A.K. Pharma?
As a licensed medicine distributor in Delhi and one of Delhi’s trusted pharmaceutical distribution companies, A.K. Pharma supplies genuine Sybrava from authorised channels to hospitals and oncology centres across India — with complete batch documentation for every supply. For hospitals managing HER2-positive breast cancer caseloads, A.K. Pharma also supplies the full range of companion medicines — Enhertu, Capecite, Kryxana, Faslodex, Truqap — simplifying specialty oncology procurement through a single distributor relationship. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827, or visit akpharma.in.
Disclaimer: This article is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. All treatment decisions for HER2-positive breast cancer, including drug selection, combination regimens, and dosing, should be made by a qualified oncologist in accordance with the approved prescribing information and current clinical guidelines. A.K. Pharma is a licensed medicine distributor and does not provide clinical guidance.